- Report
- April 2018
- 195 Pages
Global
From €13310EUR$14,995USD£11,455GBP
- Report
- June 2024
- 105 Pages
Global
From €13310EUR$14,995USD£11,455GBP
- Report
- March 2021
- 48 Pages
Global
€19528EUR$22,000USD£16,807GBP
- Report
- September 2022
- 58 Pages
Global
From €1775EUR$2,000USD£1,528GBP
Teriparatide is a synthetic form of parathyroid hormone used to treat endocrine and metabolic disorders. It is used to treat osteoporosis in postmenopausal women and men at high risk of fracture, as well as to treat osteoporosis in men and women with glucocorticoid-induced osteoporosis. It is also used to treat Paget's disease of bone in adults. Teriparatide is administered as a subcutaneous injection and is available in both brand-name and generic forms.
Teriparatide is a relatively new drug in the endocrine and metabolic disorders market, but it has been gaining traction in recent years. It is a safe and effective treatment for osteoporosis and other bone-related disorders, and its use is expected to continue to grow.
Some companies in the Teriparatide market include Eli Lilly, Amgen, and Teva Pharmaceuticals. Show Less Read more